TY - JOUR
T1 - Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women
AU - Ruiz-Sternberg, Ángela María
AU - Moreira, Edson D.
AU - Restrepo, Jaime A.
AU - Lazcano-Ponce, Eduardo
AU - Cabello, Robinson
AU - Silva, Arnaldo
AU - Andrade, Rosires
AU - Revollo, Francisco
AU - Uscanga, Santos
AU - Victoria, Alejandro
AU - Guevara, Ana María
AU - Luna, Joaquín
AU - Plata, Manuel
AU - Dominguez, Claudia Nossa
AU - Fedrizzi, Edison
AU - Suarez, Eugenio
AU - Reina, Julio C.
AU - Ellison, Misoo C.
AU - Moeller, Erin
AU - Ritter, Michael
AU - Shields, Christine
AU - Cashat, Miguel
AU - Perez, Gonzalo
AU - Luxembourg, Alain
N1 - Funding Information:
Medical writing assistance was provided by Erin M. Bekes, PhD, of Complete Medical Communications, Hackensack, NJ. This assistance was funded by Merck & Co., Inc., Kenilworth, NJ, USA .
Funding Information:
Edison Fedrizzi has received grants, personal fees, and non-financial support from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, as a Principal Investigator for the V503-001 trial.
Publisher Copyright:
© 2018 Merck Sharp & Dohme Corp., and The Authors
PY - 2018/6
Y1 - 2018/6
N2 - Background: A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine. Methods: Efficacy, immunogenicity, and safety outcomes were assessed in Latin American participants enrolled in 2 international studies of the 9vHPV vaccine, including a randomized, double-blinded, controlled with qHPV vaccine, efficacy, immunogenicity, and safety study in young women aged 16–26 years, and an immunogenicity and safety study in girls and boys aged 9–15 years. Participants (N=5312) received vaccination at Day 1, Month 2, and Month 6. Gynecological swabs were collected regularly in young women for cytological and HPV DNA testing. Serum was analyzed for HPV antibodies in all participants. Adverse events (AEs) were also monitored in all participants. Results: The 9vHPV vaccine prevented HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical, vulvar, and vaginal dysplasia with 92.3% efficacy (95% confidence interval 54.4, 99.6). Anti-HPV6, 11, 16, and 18 geometric mean titers at Month 7 were similar in the 9vHPV and qHPV vaccination groups. Anti-HPV antibody responses following vaccination were higher among girls and boys than in young women. Most (>99%) 9vHPV vaccine recipients seroconverted for all 9 HPV types at Month 7. Antibody responses to the 9 HPV types persisted over 5 years. The most common AEs were injection-site related, mostly of mild to moderate intensity. Conclusions: The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Latin American young women, girls, and boys. These data support 9vHPV vaccination programs in Latin America, a region with substantial cervical cancer burden.
AB - Background: A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine. Methods: Efficacy, immunogenicity, and safety outcomes were assessed in Latin American participants enrolled in 2 international studies of the 9vHPV vaccine, including a randomized, double-blinded, controlled with qHPV vaccine, efficacy, immunogenicity, and safety study in young women aged 16–26 years, and an immunogenicity and safety study in girls and boys aged 9–15 years. Participants (N=5312) received vaccination at Day 1, Month 2, and Month 6. Gynecological swabs were collected regularly in young women for cytological and HPV DNA testing. Serum was analyzed for HPV antibodies in all participants. Adverse events (AEs) were also monitored in all participants. Results: The 9vHPV vaccine prevented HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical, vulvar, and vaginal dysplasia with 92.3% efficacy (95% confidence interval 54.4, 99.6). Anti-HPV6, 11, 16, and 18 geometric mean titers at Month 7 were similar in the 9vHPV and qHPV vaccination groups. Anti-HPV antibody responses following vaccination were higher among girls and boys than in young women. Most (>99%) 9vHPV vaccine recipients seroconverted for all 9 HPV types at Month 7. Antibody responses to the 9 HPV types persisted over 5 years. The most common AEs were injection-site related, mostly of mild to moderate intensity. Conclusions: The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Latin American young women, girls, and boys. These data support 9vHPV vaccination programs in Latin America, a region with substantial cervical cancer burden.
UR - http://www.scopus.com/inward/record.url?scp=85042942548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042942548&partnerID=8YFLogxK
U2 - 10.1016/j.pvr.2017.12.004
DO - 10.1016/j.pvr.2017.12.004
M3 - Research Article
C2 - 29269325
AN - SCOPUS:85042942548
SN - 2666-6790
VL - 5
SP - 63
EP - 74
JO - Papillomavirus Research
JF - Papillomavirus Research
ER -
